A recent panel decision by the Federal Circuit has cast doubt on a prior ruling made by a Delaware federal judge to dismiss Amarin Pharma Inc.’s infringement lawsuit against Hikma Pharmaceuticals USA Inc. The overtone of the panel’s deliberations suggests the district court’s decision may have been somewhat precipitous.
The litigation pivots around the blockbuster cardiovascular drug, Vascepa. Amarin Pharma Inc. has brought allegations of infringement against Hikma Pharmaceuticals USA Inc. relating to their limited-use rendition of the drug. The panel’s deliberations indicate a potential readiness to reevaluate the previous dismissal, although this sentiment is still developing.
Further details regarding this evolving legal matter can be accessed at Law360 through this link.